Clinical Features and Long-Term Outcomes of Anti-Leucine-Rich Glioma-Inactivated 1 Encephalitis: A Multi-Center Study
Shan Qiao,1 Huai-kuan Wu,1 Ling-ling Liu,2 Mei-ling Wang,3 Ran-ran Zhang,4 Tao Han,5 Xue-wu Liu4 1Department of Neurology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong Province 250014, People’s Republic of China; 2Department of Neurology, Liaocheng Pe...
Guardado en:
Autores principales: | Qiao S, Wu H, Liu L, Wang M, Zhang R, Han T, Liu X |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1481ee076bdd4c9b9eee10141d74039f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Autoimmune encephalitis with coexistent LGI1 and GABABR1 antibodies: case report
por: Yi Xie, et al.
Publicado: (2021) -
Clinical features of limbic encephalitis with LGI1 antibody
por: Wang ML, et al.
Publicado: (2017) -
CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Letter]
por: Wei M, et al.
Publicado: (2020) -
CXCL13 Is A Biomarker Of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients
por: Lin Y, et al.
Publicado: (2019) -
Autoimmune basal ganglia encephalitis associated with anti-recoverin antibodies: A case report
por: Yuki Kitazaki, et al.
Publicado: (2021)